Skip to main content
. Author manuscript; available in PMC: 2024 Mar 23.
Published in final edited form as: Pharmacoepidemiol Drug Saf. 2021 Mar 23;30(6):797–805. doi: 10.1002/pds.5219

TABLE 3.

Cox proportional-hazards regression results for central and peripheral nervous system dysfunction

Combined cohort Era 1 (January 1, 2000-September 14, 2004) Era 2 (September 15, 2004-September 30, 2015)



Outcome Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
CNS Dysfunction 1.08a 1.05, 1.11 <0.001 1.10 0.99, 1.22 0.08 1.08a 1.04, 1.11 <0.001
PNS 1: Symptoms 1.09 1.07, 1.11 <0.001 1.10 1.04, 1.17 <0.001 1.08 1.06, 1.10 <0.001
PNS 2: Symptoms + PN - - - 1.23a 0.83, 1.83 0.31 1.15a 1.03, 1.28 0.01
PNS 3: Symptoms + EPT - - - 1.00a 0.88, 1.14 0.97 1.12 1.06, 1.19 <0.001
PNS 4: Symptoms + PN + EPT - - - 1.04a 0.61, 1.76 0.89 1.25a 1.03, 1.52 0.03

Note: In combined cohort, Cox proportional-hazards regression analysis was only conducted for CNS dysfunction outcome and PNS symptoms outcome.

Abbreviations: CNS, central nervous system; EPT, electrophysiological testing; PN, peripheral neuropathy; PNS, peripheral nervous system.

a

Proportional hazards assumption failed and categorical time-varying analysis was performed (Table S8).